Lb Pharmaceuticals LBRX Institutional Ownership

Lb Pharmaceuticals Inc (NASDAQ:LBRX) showed up in the 13F filings of 116 institutional investors as of June 2026.

• Their combined ownership stood at 99.4% of outstanding shares in June 2026, down from 99.9% in March 2026.
• They increased total shares held in Lb Pharmaceuticals by 6.54% from the prior quarter, while the number of investors in LBRX stayed flat year over year.
• Activity in LBRX broke down as 84 buyers, 14 sellers, and 18 unchanged among 116 total holders.
• Combined, these investors held 29.95Mn shares in LBRX for June 2026, up by 1.84Mn shares quarter on quarter, and with no net change year over year.
• As of June 30, 2026, the biggest holder of Lb Pharmaceuticals is Deep Track Capital, LP at 3.35Mn shares, representing 11.12% of shares outstanding.
• The largest buyers of Lb Pharmaceuticals for the quarter ending June 2026 were BOOTHBAY FUND MANAGEMENT, LLC (275.68K), BlackRock, Inc. (263.46K), Goldman Sachs Group Inc (212.66K), Trails Edge Capital Partners, LP (203.66K), Sixth Street Partners Management Company, L.P. (195.49K).
• Top sellers of LBRX stock for the quarter ending June 2026 included TCG Crossover Management, LLC (392.18K), Logos Global Management LP (330.0K), CITADEL ADVISORS LLC (200.94K), UBS Group AG (51.98K), Russell Investments Group, Ltd. (37.99K).
• Business Quant data shows the 10 biggest positions in Lb Pharmaceuticals as of June 2026 are held by Deep Track Capital, LP (3.35Mn), BlackRock, Inc. (2.73Mn), RA CAPITAL MANAGEMENT, L.P. (2.21Mn), Trails Edge Capital Partners, LP (1.52Mn), Commodore Capital LP (1.5Mn), Jpmorgan Chase & Co (1.5Mn), TCG Crossover Management, LLC (1.45Mn), Caligan Partners LP (1.44Mn), Spruce Street Capital LP (1.38Mn), Nantahala Capital Management, LLC (1.05Mn).